BrainsWay (BWAY) announced the FDA has granted an expanded indication for the company's Deep Transcranial Magnetic Stimulation system or Deep TMS allowing for the treatment of patients with major depressive disorder ages 22 to 86, changing the previous upper age limit of 68. The company noted that, Deep TMS is the only TMS Device indicated for depression treatment in patients between the ages of 68 and 86.

BrainsWay（BWAY）宣布，FDA已批准该公司的深度经颅磁刺激系统或深度TMS扩大适应症，允许治疗22至86岁的重度抑郁症患者，从而改变了先前的68岁上限。该公司指出，Deep TMS是唯一适用于68至86岁患者抑郁症治疗的TMS设备。

'This significant development presents an exciting business opportunity for BrainsWay,' said Hadar Levy, Chief Executive Officer of BrainsWay. For More Such Health News, visit rttnews.com. For comments and feedback contact: editorial@rttnews.comBusiness News.

BrainsWay首席执行官哈达尔·利维（HadarLevy）说，这一重大发展为BrainsWay带来了令人兴奋的商机。有关更多此类健康新闻，请访问rttnews.com。如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。